Highly active antiretroviral therapy improved persistent lamivudine-resistant viremia in acute hepatitis B virus genotype Ae infection with coinfection of human immunodeficiency virus

Hepatology Research

Volumn 40, Issue 2, 2010, Pages 229-235

  Aizawa, Mashu ^a   Tsubota, Akihito ^a,b   Fujise, Kiyotaka ^a   Kato, Tetsuro ^b   Sakamoto, Mitsuo ^b   Ohkusa, Toshifumi ^a   Tajiri, Hisao ^b  

^a JIKEI UNIVERSITY SCHOOL OF MEDICINE   (Japan)

^b JIKEI UNIVERSITY SCHOOL OF MEDICINE   (Japan)

Author keywords

Acute hepatitis B; Genotype; Highly active antiretroviral therapy; Human immunodeficiency virus

Indexed keywords

ADEFOVIR DIPIVOXIL; HUMAN IMMUNODEFICIENCY VIRUS ANTIBODY; LAMIVUDINE; TENOFOVIR DISOPROXIL;

ABNORMAL LABORATORY RESULT; ACUTE HEPATITIS; ADULT; ARTICLE; CASE REPORT; CD4 LYMPHOCYTE COUNT; COMBINATION CHEMOTHERAPY; DRUG EFFICACY; DRUG SUBSTITUTION; EARLY DIAGNOSIS; EARLY INTERVENTION; FATIGUE; FOLLOW UP; GENE MUTATION; GENETIC ANALYSIS; HEPATITIS B; HEPATITIS B VIRUS GENOTYPE AE; HIGHLY ACTIVE ANTIRETROVIRAL THERAPY; HOMOSEXUALITY; HOSPITAL ADMISSION; HUMAN; HUMAN IMMUNODEFICIENCY VIRUS INFECTION; HUMAN TISSUE; JAPAN; LIVER BIOPSY; MALE; MIXED INFECTION; NONHUMAN; PRIORITY JOURNAL; SEQUENTIAL ANALYSIS; TREATMENT DURATION; TREATMENT RESPONSE; VIREMIA; VIRUS STRAIN;

EID: 77954366327     PISSN: 13866346     EISSN: 1872034X     Source Type: Journal    
DOI: 10.1111/j.1872-034X.2009.00570.x     Document Type: Article

References (26)

1. Alter MJ. Epidemiology of viral hepatitis and HIV co-infection. J Hepatol 2006, 44:S6-9.
2. Koike K, Kikuchi Y, Kato M. Prevalence of hepatitis B virus infection in Japanese patients with HIV. Hepatol Res 2008, 38:310-14.
3. Orito E, Ichida T, Sakugawa H. Geographic distribution of hepatitis B virus (HBV) genotype in patients with chronic HBV infection in Japan. Hepatology 2001, 34:590-4.
4. Kobayashi M, Arase Y, Ikeda K, Tsubota A. Clinical features of hepatitis B virus genotype A in Japanese patients. J Gastroenterol 2003, 38:656-62.
5. Yamada N, Yotuyanagi H, Koitabashi Y. Epidemiology and clinical features of acute hepatitis B in Japan - Analysis with an emphasis on genotype A HBV. Kanzo 2008, 49:553-9.
6. Hadler SC, Judson FN, O'Malley PM. Outcome of hepatitis B virus infection in homosexual men and its relation to prior human immunodeficiency virus infection. J Infect Dis 1991, 163:454-9.
7. Suzuki Y, Kobayashi M, Ikeda K. Persistence of acute infection with hepatitis B virus genotype A and treatment in Japan. J Medical Virol 2005, 76:33-9.
8. Usuda S, Okamoto H, Iwanari H. Serological detection of hepatitis B virus genotypes by ELISA with monoclonal antibodies to type-specific epitopes in the preS2-region product. J Virol Methods 1999, 80:97-112.
9. Ichida F, Tsuji T, Omata M. New Inuyama Classi-fication; new criteria for histological assessment of chronic hepatitis. Int Hepatol Commun 1996, 6:112-19.
10. Schildgen O, Sirma H, Funk A. Variant of hepatitis B virus with primary resistance to adefovir. N Engl J Med 2006, 354:1807-12.
11. Shaw T, Bartholomeusz A, Locarnini S. HBV drug resistance: mechanisms, detection and interpretation. J Hepatol 2006, 44:593-606.
12. Angus P, Vaughan R, Xiong S. Resistance to adefovir dipivoxil therapy associated with the selection of a novel mutation in the HBV polymerase. Gastroenterology 2003, 125:292-7.
13. Koibuchi T, Hitani A, Nakamura T. Predominance of genotype A HBV in an HBV-HIV-1 dually positive population compared with an HIV-1-Negative counterpart in Japan. J Med Virol 2001, 64:435-40.
14. Omori K, Nobiyyuki T, Hasegawa K, Hashimoto E, Shiratori K. Analysis of patients who received lamivudine for acute hepatitis B of genotype A. Kanzo 2007, 48:145-52.
15. Abagiu AO, Duna FM, Radulescu CA. Lamivudine in severe acute viral B hepatitis. J Hepatol 2003, 38:121.
16. Schmilovitz-Weiss H, Ben-Ari Z, Sikuler E. Lamivudine treatment for acute severe hepatitis B: a pilot study. Liver Int 2004, 24:547-51.
17. Lok AS, McMahon BJ. Chronic hepatitis B. Hepatology 2007, 45:507-39.
18. Erhardt A, Blondin D, Hauck K. Response to interferon alfa is hepatitis B virus genotype dependent: genotype A is more sensitive to interferon than genotype D. Gut 2005, 54:1009-13.
19. Thio C, Locarnini S. Treatment of HIV/HBV coinfection: clinical and virological issues. AIDS Rev 2007, 9:40-53.
20. McMahon MA, Jilek BL, Brennan TP. The HBV drug entecavir - effects on HIV-1 replication and resistance. N Engl J Med 2007, 356:2614-21.
21. Kanda A, Takehara T, Ohkawa K. Early emergence of entecavir-resistant hepatitis B virus in a patient with hepatitis B virus/human immunodeficiency virus coinfection. Hepatol Res 2008, 38:622-8.
22. Peters MG, Andersen J, Lynch P. Randomized controlled study of tenofovir and adefovir in chronic hepatitis B virus and HIV infection: ACTG A5127. Hepatology 2006, 44:1110-16.
23. Ying C, De Clercq E, Nicholson W. Inhibition of the replication of the DNA polymerase M550V mutation variant of human hepatitis B virus by adefovir, tenofovir, L-FMAU, DAPD, penciclovir and lobucavir. J Viral Hepat 2000, 7:161-5.
24. Margot NA, Waters JM, Miller MD. In vitro human immunodeficiency virus Type 1 resistance selections with combinations of tenofovir and emtricitabine or abacavir and lamivudine. Antimicrob Agents Chemother 2006, 50:4087-95.
25. van Bommel F, Zollner B, Sarrazin C. Tenofovir for patients with lamivudine-resistant hepatitis B virus (HBV) infection and high HBV DNA level during adefovir therapy. Hepatology 2006, 44:318-25.
26. Schildgen O, Schewe CK, Vogelc M. Successful therapy of hepatitis B with tenofovir in HIV-infected patients failing previous adefovir and lamivudine treatment. AIDS 2004, 18:2325-41.